Clinical trial
A Phase 1, Multicenter, Open-label, Dose-Finding Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection of INS1202 in Patients With Amyotrophic Lateral Sclerosis
NCT07290062 is registered in ClinicalTrials.gov with Insmed Gene Therapy LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Open-label, Dose-Finding Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection of INS1202 in Patients With Amyotrophic Lateral Sclerosis
- Lead sponsor
- Insmed Gene Therapy LLC
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- January 9, 2026
- Completion date
- March 31, 2030
- Enrollment
- 23 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.